• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    4/12/23 9:06:13 AM ET
    $AGLE
    $AKTX
    $CELZ
    $CUTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGLE alert in real time by email

    Gainers

    • Creative Medical Tech (NASDAQ:CELZ) shares increased by 154.1% to $1.23 during Wednesday's pre-market session. The market value of their outstanding shares is at $17.3 million.
    • Cyclo Therapeutics (NASDAQ:CYTH) stock rose 22.47% to $0.85. The company's market cap stands at $8.9 million.
    • NeuroOne Medical Tech (NASDAQ:NMTC) shares increased by 11.48% to $1.99. The company's market cap stands at $32.5 million.
    • Exscientia (NASDAQ:EXAI) stock increased by 9.66% to $5.98. The market value of their outstanding shares is at $737.1 million.
    • Akari Therapeutics (NASDAQ:AKTX) stock rose 9.58% to $0.2. The market value of their outstanding shares is at $14.8 million.
    • GT Biopharma (NASDAQ:GTBP) shares rose 9.01% to $0.57. The market value of their outstanding shares is at $20.8 million.

    Losers

    • PLx Pharma (NASDAQ:PLXP) shares decreased by 29.3% to $0.09 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.4 million.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares fell 26.22% to $0.19. The company's market cap stands at $12.4 million.
    • Innovative Eyewear (NASDAQ:LUCY) shares declined by 15.69% to $3.71. The market value of their outstanding shares is at $28.6 million.
    • GlucoTrack (NASDAQ:GCTK) shares declined by 13.78% to $1.69. The market value of their outstanding shares is at $26.2 million.
    • Landos Biopharma (NASDAQ:LABP) stock fell 9.73% to $0.26. The company's market cap stands at $8.1 million.
    • Cutera (NASDAQ:CUTR) stock declined by 9.5% to $24.5. The market value of their outstanding shares is at $484.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $AKTX
    $CELZ
    $CUTR

    CompanyDatePrice TargetRatingAnalyst
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    NeuroOne Medical Technologies Corporation
    $NMTC
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    GT Biopharma Inc.
    $GTBP
    12/2/2024$11.00Buy
    ROTH MKM
    Exscientia Plc
    $EXAI
    7/9/2024Buy
    TD Cowen
    Cutera Inc.
    $CUTR
    3/22/2024Underperform → Mkt Perform
    William Blair
    Exscientia Plc
    $EXAI
    1/5/2024$11.00 → $9.00Buy → Neutral
    BofA Securities
    Cutera Inc.
    $CUTR
    7/27/2023$14.00 → $18.00Underweight → Neutral
    Piper Sandler
    More analyst ratings

    $AGLE
    $AKTX
    $CELZ
    $CUTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $AGLE
    $AKTX
    $CELZ
    $CUTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GT Biopharma to Participate in the 38th Annual Roth Conference

    SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will participate in the 38th Annual Roth Conference being held March 22-24, 2026 in Laguna Niguel, CA. 38th Annual Roth Conference Format: Presentation and 1x1 investor meetingsPresentation Date: Tuesday, March 24th, 2026Time: 1:30 PM PDT The Company will be available for one-on-one meetings at the conference

    3/11/26 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Glucotrack to Present at LSI USA '26 Medtech Innovation Summit

    RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer, will present at LSI USA '26 Summit, taking place March 16-20, 2026, in Dana Point, California. The presentation will take place on Tuesday, March 17 at 8:15 a.m. PT. Dr. Goode will introduce Glucotrack's continuous blood glucose monitor (CBGM) technology, share its positive first-in-human study results, outline the Company's regulatory strategy and commercialization

    3/10/26 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $AGLE
    $AKTX
    $CELZ
    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Akari Therapeutics with a new price target

    Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00

    7/18/25 9:02:34 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target

    Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45

    5/5/25 8:32:14 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $AGLE
    $AKTX
    $CELZ
    $CUTR
    SEC Filings

    View All

    SEC Form DEF 14A filed by NeuroOne Medical Technologies Corporation

    DEF 14A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    3/9/26 8:00:30 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 10-Q/A filed by GT Biopharma Inc.

    10-Q/A - GT Biopharma, Inc. (0000109657) (Filer)

    3/6/26 4:01:05 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-Q/A filed by GT Biopharma Inc.

    10-Q/A - GT Biopharma, Inc. (0000109657) (Filer)

    3/6/26 4:01:09 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $AKTX
    $CELZ
    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Wambeke David J.

    3 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:39:31 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Mertens Steve covered exercise/tax liability with 7,376 shares, decreasing direct ownership by 5% to 153,047 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:27:42 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $AGLE
    $AKTX
    $CELZ
    $CUTR
    Leadership Updates

    Live Leadership Updates

    View All

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, "Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused discoveries toward clinical relevance make her an outstandin

    2/23/26 8:50:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $AGLE
    $AKTX
    $CELZ
    $CUTR
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $AGLE
    $AKTX
    $CELZ
    $CUTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exscientia Plc

    SC 13G/A - Exscientia plc (0001865408) (Subject)

    11/22/24 9:11:55 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care